SH2 domain containing 1A
OMIM: 300490, Gene2Phenotype
Panel | Reviews | Mode of inheritance | Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SH2D1A in Infantile enterocolitis & monogenic inflammatory bowel disease
Level 3: Gastrointestinal disorders
|
review | X-LINKED: hemizygous mutation in males, monoallelic mutations in females may cause disease (may be less severe, later onset than males) |
Sources
Phenotypes
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SH2D1A in Haematological malignancies for rare disease
Level 3: Tumour syndromes
|
review | X-LINKED: hemizygous mutation in males, biallelic mutations in females |
Sources
Phenotypes
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SH2D1A in Gastrointestinal epithelial barrier disorders
Level 3: Gastrointestinal disorders
|
review | X-LINKED: hemizygous mutation in males, monoallelic mutations in females may cause disease (may be less severe, later onset than males) |
Sources
Phenotypes
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SH2D1A in COVID-19 research
|
review | X-LINKED: hemizygous mutation in males, biallelic mutations in females |
Sources
Phenotypes
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SH2D1A in Primary immunodeficiency or monogenic inflammatory bowel disease
|
review | X-LINKED: hemizygous mutation in males, biallelic mutations in females |
Sources
Phenotypes
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SH2D1A in Haematological malignancies cancer susceptibility
Level 3: Pertinent cancer susceptibility gene panel
|
review | X-LINKED: hemizygous mutation in males, biallelic mutations in females |
Sources
Phenotypes
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SH2D1A in Severe Paediatric Disorders
|
review | X-LINKED: hemizygous mutation in males, biallelic mutations in females |
Sources
Phenotypes
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SH2D1A in Lymphoproliferative syndrome with absent SAP expression
|
review | X-LINKED: hemizygous mutation in males, biallelic mutations in females |
Sources
|